Balance Sheet
Cash Flow Statement
AcquisitionsAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Haemonetics (HAE) Acquisitions (2020 - 2024)

Haemonetics (HAE) has 9 years of Acquisitions data on record, last reported at $1.8 million in Q3 2024.

  • For Q3 2024, Acquisitions changed N/A year-over-year to $1.8 million; the TTM value through Jun 2025 reached $1.8 million, down 99.55%, while the annual FY2025 figure was $150.9 million, 38.12% down from the prior year.
  • Acquisitions reached $1.8 million in Q3 2024 per HAE's latest filing, down from $149.2 million in the prior quarter.
  • Across five years, Acquisitions topped out at $418.2 million in Q2 2021 and bottomed at $1.8 million in Q3 2024.
  • Average Acquisitions over 5 years is $119.3 million, with a median of $16.6 million recorded in 2020.
  • Peak YoY movement for Acquisitions: tumbled 84.95% in 2021, then increased 14.0% in 2022.
  • A 5-year view of Acquisitions shows it stood at $16.6 million in 2020, then crashed by 84.95% to $2.5 million in 2021, then grew by 14.0% to $2.8 million in 2022, then soared by 8456.21% to $243.9 million in 2023, then tumbled by 99.28% to $1.8 million in 2024.
  • Per Business Quant database, its latest 3 readings for Acquisitions were $1.8 million in Q3 2024, $149.2 million in Q2 2024, and $243.9 million in Q4 2023.